Jae Park
Memorial Sloan Kettering Cancer Center · Study Principal Investigator · National Cancer Center, Korea
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jae Park as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:46 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07313852 · A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic LeukemiaMemorial Sloan Kettering Cancer Center · not yet recruiting · B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALL · principal investigator
- Ph2NCT06561360 · A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)Memorial Sloan Kettering Cancer Center · recruiting · Hairy Cell Leukemia · principal investigator
- Ph1NCT06287528 · A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)Memorial Sloan Kettering Cancer Center · recruiting · Philadelphia-Negative ALL, Philadelphia-Positive ALL, Relapsed ALL, Adult · principal investigator
- Ph1NCT05757700 · Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell LymphomaMemorial Sloan Kettering Cancer Center · active not recruiting · B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes · principal investigator
- Ph1NCT05748197 · A Study of ADCLEC.syn1 in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center · recruiting · Acute Myeloid Leukemia · principal investigator
- Early Ph1NCT05386576 · A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)Memorial Sloan Kettering Cancer Center · active not recruiting · Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT04464200 · 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell CancersMemorial Sloan Kettering Cancer Center · active not recruiting · Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma · principal investigator
- Ph2NCT04148430 · A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell TherapyMemorial Sloan Kettering Cancer Center · active not recruiting · B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma · principal investigator
- Ph2NCT03410875 · A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell LeukemiaMemorial Sloan Kettering Cancer Center · active not recruiting · Hairy Cell Leukemia, Leukemia, Leukemia, Hairy Cell · principal investigator
- Ph1NCT03085173 · A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic MalignanciesMemorial Sloan Kettering Cancer Center · active not recruiting · Chronic Lymphocytic Leukemia (CLL), Relapsed, Refractory · principal investigator
- Ph1NCT02647190 · Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or OlderMemorial Sloan Kettering Cancer Center · withdrawn · Acute Lymphoblastic Leukemia (ALL), Newly Diagnosed Philadelphia Chromosome Negative, Aged 60 Years or Older · principal investigator
- Ph2NCT02628860 · Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating PancreatoduodenectomyNational Cancer Center, Korea · completed · Pancreatic Cancer, Anemia · principal investigator
- Ph1NCT02494882 · Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or OlderMemorial Sloan Kettering Cancer Center · active not recruiting · Acute Lymphoblastic Leukemia · principal investigator
- N/ANCT02479984 · Diagnostic Laparoscopy in the Preoperative Staging of Pancreatobiliary CancerNational Cancer Center, Korea · unknown · Pancreatic Cancer · principal investigator
- Ph3NCT01937806 · Phase 3 and Extensional Study of BesifovirIlDong Pharmaceutical Co Ltd · unknown · Chronic Hepatitis B · principal investigator
- Ph2NCT01920737 · A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic LeukemiaMemorial Sloan Kettering Cancer Center · active not recruiting · Leukemia · principal investigator
- Ph1NCT01416974 · Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and RituximabMemorial Sloan Kettering Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT01404949 · Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission TherapyMemorial Sloan Kettering Cancer Center · completed · Acute Promyelocytic Leukemia · principal investigator
- Ph2NCT01333124 · Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic CarcinomaNational Cancer Center, Korea · terminated · Resectable Pancreatic Carcinoma · principal investigator
- Ph1NCT01044069 · Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19Memorial Sloan Kettering Cancer Center · active not recruiting · Leukemia, Acute Lymphoblastic Leukemia · principal investigator
- Ph1/Ph2NCT00466531 · Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19Memorial Sloan Kettering Cancer Center · active not recruiting · Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 15 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Project 4: Cooperative CAR T cell therapy in AML patientsP50CA254838 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2026 · $410,938 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:46 UTC. The ranking covers the 200 most relevant of 2804 PubMed records, and a shared surname and initials can bring in a namesake. All 2804 on PubMed
- 1,063 citationsRCR 99.5
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol · 20221,010 citationsRCR 72.7
- 778 citationsRCR 69.3
- 627 citationsRCR 54.7
- 371 citationsRCR 87.5
- Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.Lancet Gastroenterol Hepatol · 2024300 citationsRCR 38.0
- Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.J Clin Oncol · 2022217 citationsRCR 13.8
- Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.Circulation · 2022200 citationsRCR 14.2
- Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).J Clin Oncol · 2024180 citationsRCR 18.8
- Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.Circulation · 2023159 citationsRCR 17.0